This study investigates KRASG12D mutation-positive locally advanced or metastatic solid tumors. The purpose of this study is to explore the effects of an investigational medication when combined with another treatment.
The study evaluates the safety and effectiveness of the investigational medication combination. It looks at how well the treatment works against tumors and checks for any side effects.
- Who can participate: Adults aged 18 and older with locally advanced or metastatic solid tumors that are KRASG12D mutation-positive can participate. Participants must have at least one measurable lesion and meet specific health criteria.
- Study details: Participants will receive an investigational medication in combination with another treatment. A placebo may be part of the study.
How understandable was the trial content above?
Hard to understand
Easy to understand